Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 10,393 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 10,393 shares of the stock in a transaction on Monday, August 18th. The shares were sold at an average price of $20.02, for a total value of $208,067.86. Following the completion of the sale, the chief executive officer directly owned 929,999 shares of the company’s stock, valued at $18,618,579.98. The trade was a 1.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, August 19th, Samuel Kintz sold 590 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $11,800.00.
• On Thursday, July 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total value of $281,500.00.
• On Tuesday, June 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.18, for a total value of $277,250.00.
• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.05, for a total value of $150,375.00.

Enliven Therapeutics Trading Up 5.1%

NASDAQ ELVN opened at $20.85 on Friday. The firm has a market capitalization of $1.24 billion, a P/E ratio of -10.43 and a beta of 0.93. The business has a fifty day simple moving average of $20.61 and a 200 day simple moving average of $19.87. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Jones Trading reduced their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a research note on Friday, May 16th. HC Wainwright upped their price objective on Enliven Therapeutics from $40.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, July 2nd. Robert W. Baird upped their price objective on Enliven Therapeutics from $40.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, June 16th. Finally, The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research note on Monday, June 16th. They issued a “buy” rating and a $37.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Buy” and an average target price of $41.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock worth $36,000 after acquiring an additional 1,114 shares during the period. GAMMA Investing LLC grew its stake in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company’s stock worth $53,000 after acquiring an additional 2,630 shares during the period. Quantbot Technologies LP bought a new position in shares of Enliven Therapeutics during the 1st quarter worth $60,000. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after acquiring an additional 930 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after acquiring an additional 3,490 shares during the period. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.